查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152356

重組疫苗契約製造市場規模、佔有率和趨勢分析報告：按疫苗類型、服務、表達平台、工作流程、治療領域、最終用途、地區和細分市場預測（2026-2033 年）

Recombinant Vaccine Contract Manufacturing Market Size, Share & Trends Analysis Report By Vaccine Type, By Service, By Expression Platform, By Workflow, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 250 Pages | 商品交期: 2-10個工作天內

價格

重組疫苗契約製造市場概述

預計到 2025 年，全球重組疫苗契約製造市場價值將達到 27 億美元，到 2026 年將成長至 29 億美元，到 2033 年將達到 60 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 10.8%。

北美市場領先，預計到 2025 年將佔據 43.7% 的最大銷售佔有率。市場成長的促進因素包括疫苗研發管線的擴張、外包的日益普及、製造流程的日益複雜以及對靈活生產能力的需求。

製藥和生物技術公司正在感染疾病和腫瘤領域開發疫苗，這些疫苗利用重組蛋白、類病毒顆粒、病毒載體、DNA和mRNA等技術。這些平台需要專門的表達系統、細胞株開發、上游工程、純化、製劑、分析測試以及符合GMP規範的生產。契約製造製造商提供這些服務，無需研發人員投資建造專用設施、設備和聘請技術人員，預計這一趨勢將推動市場成長。

合約研發生產機構 (CDMO) 透過提供從臨床到商業化的可擴展基礎設施來支持疫苗生產。柔軟性的生物反應器、一次性系統、模組化生產套件和多產品設施使申辦者能夠從小小規模臨床生產開始，並隨著候選藥物向商業化而逐步提高產量。一體化供應商還負責協調製程開發、原料藥)生產、填充和包裝、穩定性測試、包裝以及法規遵循。這減少了技術轉移需求，縮短了開發週期，提高了品管，並降低了執行風險。契約製造製造商還支持從實驗室到生產設施的技術轉移，幫助開發人員將實驗流程轉化為檢驗且可重複的商業化生產。

新興生技公司的持續湧入進一步強化了外包需求，因為這些研發公司往往缺乏內部生產能力和監管經驗。政府在應對疫情、本地疫苗生產和供應鏈韌性方面的投資也為國內和區域合約研發生產機構（CDMO）創造了商機。製藥公司正日益實現生產網路多元化，以減少對單一生產基地的依賴，並確保在需求激增期間的產能，這也促進了市場成長。

基因改造細胞株、高密度培養、連續生產製程、自動化、先進層析法和即時製程監控等方面的技術進步，正在提高抗原產量和批間一致性。合約研發生產機構（CDMO）透過將這些技術的成本分攤到多個客戶身上，促進了先進生產技術的普及。因此，契約製造透過降低資本門檻、提供專業知識、加速規模化生產、提高供應柔軟性，以及幫助研發人員將更多候選材料從研究階段推進到商業化供應階段，擴大了疫苗生產規模。

目錄

第1章 研究方法和範圍

第2章執行摘要

第3章：重組疫苗契約製造市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 科技情勢
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
  • 市場分析工具

第4章：重組疫苗契約製造市場：依疫苗類型分類的估算與趨勢分析

  • 按疫苗類型分類的市場佔有率，2025 年和 2033 年
  • 重組疫苗契約製造市場：按疫苗類型分類的趨勢分析
  • 全球重組疫苗契約製造市場：按疫苗類型分類的規模和趨勢分析（2021-2033年）
  • 重組蛋白/次單位疫苗
  • 類病毒顆粒（VLP）疫苗
  • 重組病毒載體疫苗
  • 重組DNA/mRNA疫苗
  • 其他

第5章：重組疫苗契約製造市場：按服務類型分類的估算與趨勢分析

  • 按服務分類的市場佔有率，2025 年和 2033 年
  • 重組疫苗契約製造市場：按服務類型分類的趨勢分析
  • 全球重組疫苗契約製造市場：基於服務的規模和趨勢分析，2021-2033年
  • API生產
  • 成品藥的生產

第6章 重組疫苗契約製造市場：基於表達平台的估算與趨勢分析

  • 按表達平台分類的市場佔有率（2025 年和 2033 年）
  • 全球重組疫苗契約製造市場：基於表達平台的趨勢分析
  • 全球重組疫苗契約製造市場規模及趨勢分析（按表達平台分類）（2021-2033 年）
  • 哺乳動物細胞表達
  • 微生物表達
  • 基於細胞的表達
  • 植物來源的表達
  • 其他

第7章 重組疫苗契約製造市場：依工作流程分類的估算與趨勢分析

  • 按工作流程分類的市場佔有率，2025 年和 2033 年
  • 全球重組疫苗契約製造市場：工作流程分析
  • 全球重組疫苗契約製造市場：基於工作流程的規模和趨勢分析，2021-2033年
  • 臨床階段
  • 商業的

第8章：重組疫苗契約製造市場：按治療領域分類的估算與趨勢分析

  • 按治療區域分類的市場佔有率，2025 年和 2033 年
  • 全球重組疫苗契約製造市場：按治療領域分類的趨勢分析
  • 全球重組疫苗契約製造市場：按治療領域分類的規模和趨勢分析（2021-2033年）
  • 感染疾病
  • 腫瘤學
  • 神經病變
  • 其他用途

第9章：重組疫苗契約製造市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率，2025 年和 2033 年
  • 重組疫苗契約製造市場：依最終用途分類的趨勢分析
  • 全球重組疫苗契約製造市場：按最終用途分類的規模和趨勢分析（2021-2033年）
  • 製藥公司
  • 生技公司
  • 學術和研究機構
  • 其他

第10章：重組疫苗契約製造市場：區域估算與趨勢分析

  • 區域市場概覽
  • 重組疫苗契約製造市場：區域趨勢分析
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲重組疫苗契約製造市場估算與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區重組疫苗契約製造市場估算與預測，2021-2033年
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2021-2033年拉丁美洲重組疫苗契約製造市場估算與預測
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特
    • 阿曼
    • 卡達

第11章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • FUJIFILM Diosynth Biotechnologies
    • WuXi Biologics
    • IDT Biologika
    • Lonza
    • Thermo Fisher Scientific（Patheon）
    • AGC Biologics
    • KBI Biopharma
    • Ajinomoto Bio-Pharma Services
    • Recipharm
    • SK bioscience
    • Northway Biotech
    • Batavia Biosciences
    • 3P Biopharmaceuticals
    • Biofabri
    • Biological E. Limited
Product Code: GVR-4-68041-053-3

Recombinant Vaccine Contract Manufacturing Market Summary

The global recombinant vaccine contract manufacturing market size was valued at USD 2.7 billion in 2025 and is projected to grow from USD 2.9 billion in 2026 to USD 6.0 billion by 2033, at a CAGR of 10.8% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.7% in 2025. Market growth is driven by expanding vaccine pipelines, rising adoption of outsourcing, increasing manufacturing complexity, and demand for flexible production capacity.

Pharmaceutical and biotechnology companies are developing recombinant proteins, virus-like particles, viral vectors, DNA, and mRNA-enabled vaccines across infectious diseases and oncology. These platforms require specialized expression systems, cell-line development, upstream processing, purification, formulation, analytical testing, and GMP-compliant production. Thus, contract manufacturers provide these capabilities without requiring developers to invest in dedicated facilities, equipment, and technical personnel, a trend expected to drive market growth.

CDMOs are fueling vaccine production by providing scalable infrastructure across clinical and commercial stages. Flexible bioreactors, single-use systems, modular manufacturing suites, and multiproduct facilities enable sponsors to begin with small clinical batches and increase production as candidates progress toward commercialization. Integrated providers also connect process development, drug-substance manufacturing, fill-finish, stability testing, packaging, and regulatory support. This reduces technology-transfer requirements, shortens development timelines, improves quality oversight, and lowers execution risks. Contract manufacturers also support technology transfer from laboratories to production facilities, helping developers convert experimental processes into validated, reproducible commercial operations.

Growing participation by emerging biotechnology companies further strengthens outsourcing demand, as these developers often lack internal manufacturing capacity and regulatory experience. Government investments in pandemic preparedness, vaccine localization, and supply-chain resilience are also generating opportunities for domestic and regional CDMOs. Pharmaceutical companies are increasingly diversifying their manufacturing networks to reduce dependence on individual sites and secure capacity during demand surges, further contributing to market growth.

Technological advances in engineered cell lines, high-density culture, continuous processing, automation, advanced chromatography, and real-time process monitoring are improving antigen yields and batch consistency. CDMOs spread the cost of these technologies across multiple clients, making advanced manufacturing more accessible. Consequently, contract manufacturing is expanding vaccine production by reducing capital barriers, providing specialized expertise, accelerating scale-up, improving supply flexibility, and enabling developers to advance more candidates from research through commercial supply.

Global Recombinant Vaccine Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global recombinant vaccine contract manufacturing market report based on vaccine type, service, expression platform, workflow, therapeutic area, end use, and region:

  • Vaccine Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Recombinant Protein/Subunit Vaccines
  • Virus-Like Particle (VLP) Vaccines
  • Recombinant Viral Vector Vaccines
  • Recombinant DNA/mRNA-Enabled Vaccines
  • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • API Manufacturing
  • Finished Drug Products Manufacturing
  • Expression Platform Outlook (Revenue, USD Million, 2021 - 2033)
  • Mammalian Cell Expression
  • Microbial Expression
  • Cell-Based Expression
  • Plant-Based Expression
  • Others
  • Workflow (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area (Revenue, USD Million, 2021 - 2033)
  • Infectious Diseases
  • Oncology
  • Neurological Disorders
  • Other Applications
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic and Research Institutions
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vaccine Type
    • 1.2.2. Service
    • 1.2.3. Expression Platform
    • 1.2.4. Workflow
    • 1.2.5. Therapeutic Area
    • 1.2.6. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Recombinant Vaccine Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity
    • 3.2.4. Market Challenges
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL Analysis

Chapter 4. Recombinant Vaccine Contract Manufacturing Market: Vaccine Type Estimates & Trend Analysis

  • 4.1. Vaccine Type Market Share, 2025 & 2033
  • 4.2. Vaccine Type Segment Dashboard
  • 4.3. Recombinant Vaccine Contract Manufacturing Market: Vaccine Type Movement Analysis
  • 4.4. Global Recombinant Vaccine Contract Manufacturing Market Size & Trend Analysis, by Vaccine Type, 2021 to 2033 (USD Million)
  • 4.5. Recombinant Protein/Subunit Vaccines
    • 4.5.1. Recombinant Protein/Subunit Vaccines Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.6. Virus-Like Particle (VLP) Vaccines
    • 4.6.1. Virus-Like Particle (VLP) Vaccines Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.7. Recombinant Viral Vector Vaccines
    • 4.7.1. Recombinant Viral Vector Vaccines Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.8. Recombinant DNA/mRNA-Enabled Vaccines
    • 4.8.1. Recombinant DNA/mRNA-Enabled Vaccines Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 5. Recombinant Vaccine Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1. Service Market Share, 2025 & 2033
  • 5.2. Service Segment Dashboard
  • 5.3. Recombinant Vaccine Contract Manufacturing Market: Service Movement Analysis
  • 5.4. Global Recombinant Vaccine Contract Manufacturing Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
  • 5.5. API Manufacturing
    • 5.5.1. API Manufacturing Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 5.6. Finished Drug Products Manufacturing
    • 5.6.1. Finished Drug Products Manufacturing Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 6. Recombinant Vaccine Contract Manufacturing Market: Expression Platform Estimates & Trend Analysis

  • 6.1. Expression Platform Market Share, 2025 & 2033
  • 6.2. Expression Platform Segment Dashboard
  • 6.3. Global Recombinant Vaccine Contract Manufacturing Market: Expression Platform Movement Analysis
  • 6.4. Global Recombinant Vaccine Contract Manufacturing Market Size & Trend Analysis, by Expression Platform, 2021 to 2033 (USD Million)
  • 6.5. Mammalian Cell Expression
    • 6.5.1. Mammalian Cell Expression Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Microbial Expression
    • 6.6.1. Microbial Expression Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Cell-Based Expression
    • 6.7.1. Cell-Based Expression Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Plant-Based Expression
    • 6.8.1. Plant-Based Expression Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Recombinant Vaccine Contract Manufacturing Market: Workflow Estimates & Trend Analysis

  • 7.1. Workflow Market Share, 2025 & 2033
  • 7.2. Workflow Platform Segment Dashboard
  • 7.3. Global Recombinant Vaccine Contract Manufacturing Market: Workflow Movement Analysis
  • 7.4. Global Recombinant Vaccine Contract Manufacturing Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
  • 7.5. Clinical
    • 7.5.1. Clinical Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Commercial
    • 7.6.1. Commercial Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Recombinant Vaccine Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. Therapeutic Area Market Share, 2025 & 2033
  • 8.2. Therapeutic Area Segment Dashboard
  • 8.3. Global Recombinant Vaccine Contract Manufacturing Market: Therapeutic Area Movement Analysis
  • 8.4. Global Recombinant Vaccine Contract Manufacturing Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 8.5. Infectious Diseases
    • 8.5.1. Infectious Diseases Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Oncology
    • 8.6.1. Oncology Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Neurological Disorders
    • 8.7.1. Neurological Disorders Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Other Applications
    • 8.8.1. Other Applications Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Recombinant Vaccine Contract Manufacturing Market: End Use Estimates & Trend Analysis

  • 9.1. End Use Market Share, 2025 & 2033
  • 9.2. End Use Segment Dashboard
  • 9.3. Recombinant Vaccine Contract Manufacturing Market: End Use Movement Analysis
  • 9.4. Global Recombinant Vaccine Contract Manufacturing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 9.5. Pharmaceutical Companies
    • 9.5.1. Pharmaceutical Companies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Biotechnology Companies
    • 9.6.1. Biotechnology Companies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Academic and Research Institutions
    • 9.7.1. Academic and Research Institutions Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Others
    • 9.8.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Recombinant Vaccine Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Recombinant Vaccine Contract Manufacturing Market: Regional Movement Analysis
  • 10.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 10.4. North America
    • 10.4.1. North America Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, By Country, 2021-2033 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. U.S. Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Canada Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Mexico Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
  • 10.5. Europe
    • 10.5.1. Europe Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Framework
      • 10.5.2.4. UK Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Framework
      • 10.5.3.4. Germany Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Framework
      • 10.5.4.4. France Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Framework
      • 10.5.5.4. Italy Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Framework
      • 10.5.6.4. Spain Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Framework
      • 10.5.7.4. Denmark Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Framework
      • 10.5.8.4. Sweden Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Framework
      • 10.5.9.4. Norway Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.6.2. Japan
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Framework
      • 10.6.2.4. Japan Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.6.3. China
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Framework
      • 10.6.3.4. China Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Framework
      • 10.6.4.4. India Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Framework
      • 10.6.5.4. Australia Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.1. Key Country Dynamics
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Framework
      • 10.6.6.4. South Korea Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Framework
      • 10.6.7.4. Thailand Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Latin America Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Framework
      • 10.7.2.4. Brazil Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Framework
      • 10.7.3.4. Argentina Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
  • 10.8. Middle East and Africa
    • 10.8.1. Middle East and Africa Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Framework
      • 10.8.2.4. South Africa Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Framework
      • 10.8.3.4. Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Framework
      • 10.8.4.4. UAE Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Framework
      • 10.8.5.4. Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.8.6. Oman
      • 10.8.6.1. Key Country Dynamics
      • 10.8.6.2. Competitive Scenario
      • 10.8.6.3. Regulatory Framework
      • 10.8.6.4. Oman Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)
    • 10.8.7. Qatar
      • 10.8.7.1. Key Country Dynamics
      • 10.8.7.2. Competitive Scenario
      • 10.8.7.3. Regulatory Framework
      • 10.8.7.4. Qatar Recombinant Vaccine Contract Manufacturing Market Estimates & Forecasts, 2021-2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Participant Overview
  • 11.2. Company Market Position Analysis
  • 11.3. Company Categorization
  • 11.4. Strategy Mapping
  • 11.5. Company Profiles/Listing
    • 11.5.1. FUJIFILM Diosynth Biotechnologies
      • 11.5.1.1. Company overview
      • 11.5.1.2. Financial performance
      • 11.5.1.3. Service benchmarking
      • 11.5.1.4. Strategic initiatives
    • 11.5.2. WuXi Biologics
      • 11.5.2.1. Company overview
      • 11.5.2.2. Financial performance
      • 11.5.2.3. Service benchmarking
      • 11.5.2.4. Strategic initiatives
    • 11.5.3. IDT Biologika
      • 11.5.3.1. Company overview
      • 11.5.3.2. Financial performance
      • 11.5.3.3. Service benchmarking
      • 11.5.3.4. Strategic initiatives
    • 11.5.4. Lonza
      • 11.5.4.1. Company overview
      • 11.5.4.2. Financial performance
      • 11.5.4.3. Service benchmarking
      • 11.5.4.4. Strategic initiatives
    • 11.5.5. Thermo Fisher Scientific (Patheon)
      • 11.5.5.1. Company overview
      • 11.5.5.2. Financial performance
      • 11.5.5.3. Service benchmarking
      • 11.5.5.4. Strategic initiatives
    • 11.5.6. AGC Biologics
      • 11.5.6.1. Company overview
      • 11.5.6.2. Financial performance
      • 11.5.6.3. Service benchmarking
      • 11.5.6.4. Strategic initiatives
    • 11.5.7. KBI Biopharma
      • 11.5.7.1. Company overview
      • 11.5.7.2. Financial performance
      • 11.5.7.3. Service benchmarking
      • 11.5.7.4. Strategic initiatives
    • 11.5.8. Ajinomoto Bio-Pharma Services
      • 11.5.8.1. Company overview
      • 11.5.8.2. Financial performance
      • 11.5.8.3. Service benchmarking
      • 11.5.8.4. Strategic initiatives
    • 11.5.9. Recipharm
      • 11.5.9.1. Company overview
      • 11.5.9.2. Financial performance
      • 11.5.9.3. Service benchmarking
      • 11.5.9.4. Strategic initiatives
    • 11.5.10. SK bioscience
      • 11.5.10.1. Company overview
      • 11.5.10.2. Financial performance
      • 11.5.10.3. Service benchmarking
      • 11.5.10.4. Strategic initiatives
    • 11.5.11. Northway Biotech
      • 11.5.11.1. Company overview
      • 11.5.11.2. Financial performance
      • 11.5.11.3. Service benchmarking
      • 11.5.11.4. Strategic initiatives
    • 11.5.12. Batavia Biosciences
      • 11.5.12.1. Company overview
      • 11.5.12.2. Financial performance
      • 11.5.12.3. Service benchmarking
      • 11.5.12.4. Strategic initiatives
    • 11.5.13. 3P Biopharmaceuticals
      • 11.5.13.1. Company overview
      • 11.5.13.2. Financial performance
      • 11.5.13.3. Service benchmarking
      • 11.5.13.4. Strategic initiatives
    • 11.5.14. Biofabri
      • 11.5.14.1. Company overview
      • 11.5.14.2. Financial performance
      • 11.5.14.3. Service benchmarking
      • 11.5.14.4. Strategic initiatives
    • 11.5.15. Biological E. Limited
      • 11.5.15.1. Company overview
      • 11.5.15.2. Financial performance
      • 11.5.15.3. Service benchmarking
      • 11.5.15.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 4 Global Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 5 Global Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 6 Global Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 7 Global Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 8 Global Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 9 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 10 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 11 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 12 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 13 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 14 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 15 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 U.S. Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 17 U.S.Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 18 U.S. Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 19 U.S. Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 20 U.S. Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 21 U.S. Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 22 Canada Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 23 Canada Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 24 Canada Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 25 Canada Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 26 Canada Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 27 Canada Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 28 Mexico Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 29 Mexico Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 30 Mexico Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 31 Mexico Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 32 Mexico Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 33 Mexico Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 34 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 35 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 36 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 37 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 38 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 39 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 40 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 41 UK Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 42 UK Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 43 UK Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 44 UK Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 45 UK Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 46 UK Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 47 Germany Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 48 Germany Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 49 Germany Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 50 Germany Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 51 Germany Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 52 Germany Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 53 France Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 54 France Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 55 France Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 56 France Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 57 France Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 58 France Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 59 Italy Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 60 Italy Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 61 Italy Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 62 Italy Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 63 Italy Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 64 Italy Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 65 Spain Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 66 Spain Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 67 Spain Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 68 Spain Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 69 Spain Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 70 Spain Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 71 Denmark Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 72 Denmark Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 73 Denmark Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 74 Denmark Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 75 Denmark Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 76 Denmark Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 77 Sweden Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 78 Sweden Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 79 Sweden Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 80 Sweden Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 81 Sweden Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 82 Sweden Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 83 Norway Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 84 Norway Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 85 Norway Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 86 Norway Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 87 Norway Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 88 Norway Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 89 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 90 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 91 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 92 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 93 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 94 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 95 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 96 Japan Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 97 Japan Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 98 Japan Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 99 Japan Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 100 Japan Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 101 Japan Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 102 China Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 103 China Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 104 China Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 105 China Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 106 China Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 107 China Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 108 India Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 109 India Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 110 India Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 111 India Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 112 India Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 113 India Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 114 Australia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 115 Australia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 116 Australia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 117 Australia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 118 Australia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 119 Australia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 120 Thailand Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 121 Thailand Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 122 Thailand Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 123 Thailand Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 124 Thailand Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 125 Thailand Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 126 South Korea Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 127 South Korea Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 128 South Korea Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 129 South Korea Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 130 South Korea Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 131 South Korea Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 132 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 133 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 134 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 135 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 136 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 137 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 138 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 139 Brazil Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 140 Brazil Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 141 Brazil Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 142 Brazil Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 143 Brazil Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 144 Brazil Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 145 Argentina Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 146 Argentina Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 147 Argentina Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 148 Argentina Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 149 Argentina Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 150 Argentina Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 151 Middle East & Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 152 Middle East & Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 153 Middle East & Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 154 Middle East & Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 155 Middle East & Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 156 Middle East & Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 157 Middle East & Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 158 South Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 159 South Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 160 South Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 161 South Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 162 South Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 163 South Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 164 Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 165 Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 166 Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 167 Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 168 Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 169 Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 170 UAE Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 171 UAE Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 172 UAE Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 173 UAE Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 174 UAE Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 175 UAE Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 176 Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 177 Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 178 Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 179 Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 180 Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 181 Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 182 Oman Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 183 Oman Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 184 Oman Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 185 Oman Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 186 Oman Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 187 Oman Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 188 Qatar Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Vaccine Type, 2021 - 2033 (USD Million)
  • Table 189 Qatar Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 190 Qatar Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Expression Platform, 2021 - 2033 (USD Million)
  • Table 191 Qatar Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 192 Qatar Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 193 Qatar Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2025 (USD Million)
  • Fig. 15 Ancillary market outlook, 2025 (USD Million)
  • Fig. 16 Recombinant Vaccine Contract Manufacturing Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Recombinant Vaccine Contract Manufacturing Market: Vaccine Type outlook and key takeaways
  • Fig. 20 Recombinant Vaccine Contract Manufacturing Market: Vaccine Type movement analysis
  • Fig. 21 Recombinant Protein/Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Virus-Like Particle (VLP) Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Recombinant Viral Vector Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Recombinant DNA/mRNA-Enabled Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Recombinant Vaccine Contract Manufacturing Market: Service outlook and key takeaways
  • Fig. 27 Recombinant Vaccine Contract Manufacturing Market: Service movement analysis
  • Fig. 28 API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Recombinant Vaccine Contract Manufacturing Market: Expression Platform outlook and key takeaways
  • Fig. 31 Recombinant Vaccine Contract Manufacturing Market: Expression Platform movement analysis
  • Fig. 32 Mammalian Cell Expression Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Microbial Expression Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Cell-Based Expression Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Plant-Based Expression Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Recombinant Vaccine Contract Manufacturing Market: Workflow outlook and key takeaways
  • Fig. 38 Recombinant Vaccine Contract Manufacturing Market: Workflow movement analysis
  • Fig. 39 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Recombinant Vaccine Contract Manufacturing Market: Therapeutic Area outlook and key takeaways
  • Fig. 42 Recombinant Vaccine Contract Manufacturing Market: Therapeutic Area movement analysis
  • Fig. 43 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Other Applications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Recombinant Vaccine Contract Manufacturing Market: End Use outlook and key takeaways
  • Fig. 48 Recombinant Vaccine Contract Manufacturing Market: End Use movement analysis
  • Fig. 49 Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Academic and Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Regional Marketplace: Key Takeaways
  • Fig. 54 North America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 U.S. Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Canada Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Mexico Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Europe Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 UK Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Germany Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 France Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Italy Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Spain Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Denmark Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Sweden Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Norway Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Asia Pacific Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Japan Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 China Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 India Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Australia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Thailand Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 South Korea Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 91 Latin America Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Brazil Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Argentina Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 96 MEA Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 South Africa Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 UAE Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Saudi Arabia Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Kuwait Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 Qatar Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Oman Recombinant Vaccine Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Participant Categorization
  • Fig. 111 Company Market Position Analysis
  • Fig. 112 Strategic Framework